Bifogade filer
Vimian Interim Report Q325
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Strong revenue and earnings growth in the third quarter
- Net revenue increased 19 per cent to EUR 104.3m (87.6) with organic growth of 9 per cent
- Adjusted EBITA increased 17 per cent to EUR 25.5m (21.9), corresponding to a margin of 24.5 per cent (25.0)
- Operating profit (EBIT) of EUR 17.5m (10.1)
- Net result of EUR 6.8m (-1.9) and earnings per share before and after dilution EUR 0.01 (0.00)
- Cash flow from operating activities of EUR 10.8m (16.7)
“In the third quarter, we delivered strong revenue growth of 19 per cent to EUR 104.3 million, with healthy organic growth of 9 per cent. Adjusted EBITA grew 17 per cent, reaching EUR 25.5 million. Our largest segment Specialty Pharma, and Veterinary Services, continued to deliver strong performance, and I was pleased to see our MedTech segment returning to organic growth”, says Carl-Johan Zetterberg Boudrie, interim CEO Vimian Group.
A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.
To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q3-report-2025/dial-in
To attend the webcast:
Link: https://vimian-group.events.inderes.com/q3-report-2025
Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.